Skip to main content

Home/ Dr. Goodyear/ Group items tagged osteoporosis

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
pharmacybiz

Reverse Decision Declining Romosozumab Use For Osteoporosis - 0 views

www.pharmacy.biz/mosozumab-use-for-osteoporosis

Romosozumab-Use-For-Osteoporosis Pharmacy-Business news-UK New-treatment-for-osteoporosis-2021 Romosozumab-osteoporosis Romosozumab-NICE

shared by pharmacybiz on 07 Jan 22 - No Cached
  • pharmacybiz on 07 Jan 22
     
    More than 100 NHS clinicians have urged the National Institute for Health and Care Excellence (NICE) to change its decision - declining recommendation of romosozumab, the first new osteoporosis medication for over a decade. In a joint letter published on January 2, the clinicians warned of the consequences of barring access to the drug to those who suffer the bone-weakening disease. The joint letter, led by the Royal Osteoporosis Society (ROS), raised concern over the scarcity of the drug pipeline for osteoporosis and lack of public funding for new research. It quoted recent government research that showed the National Institute for Health Research (NIHR) invested less than £1 million in osteoporosis research in 2020-21, against the £4.6 billion per year cost to the NHS of fractures. Craig Jones, chief executive of the Royal Osteoporosis Society said: "We're calling on NICE and the applicant company to get back round the table and work with us to ensure equal access to this important new treatment.
Nathan Goodyear

The association between serum dehydroepiandrosterone sulfate (DHEA-... - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...25692973

DHEA DHEA-S DHEAS BMD osteoporosis men male hormone hormones

shared by Nathan Goodyear on 02 Mar 15 - No Cached
  • Nathan Goodyear on 02 Mar 15
     
    Only abstract available here, but lower DHEA-S (still in reference normal range) associated with lower bone mineral density and increased osteoporosis risk.
Nathan Goodyear

JAMA Network | Archives of Internal Medicine | Plasma Total Homocysteine Level and Bone... - 0 views

archinte.jamanetwork.com/article.aspx

homocysteine folate folic acid folic acid BMD women bone mineral osteoporosis density

shared by Nathan Goodyear on 23 Jul 12 - No Cached
  • Nathan Goodyear on 23 Jul 12
     
    elevated homocysteine and low folic acid levels associated with decreasing BMD in women.
Nathan Goodyear

Estrogen synthesis in human colon cancer epithelial cells | Alternative Medicine Review... - 0 views

findarticles.com/...ai_65068489

colon cancer estrogen aromatase quercetin

shared by Nathan Goodyear on 09 Feb 11 - No Cached
  • These findings demonstrate for the first time that colorectal adenocarcinoma cell lines express aromatase. Interestingly, the enzyme activity was inhibited by quercetin, one major dietary flavonoid, by tamoxifen, a hormonal therapeutic agent for breast cancer, and by raloxifene, used in the prevention of postmenopausal osteoporosis.
  • Nathan Goodyear on 09 Feb 11
     
    colon cancer cells regulated by Estrogen through aromatase activity
Nathan Goodyear

Testosterone Deficiency, Cardiac Health, and Older Men - 0 views

www.ncbi.nlm.nih.gov/...PMC4000629

low T low Testosterone hypogonadism men male hormone hormones Testosterone therapy disease diabetes metabolic syndrome osteoporosis HIV infertility opiates

shared by Nathan Goodyear on 27 Jan 15 - No Cached
  • 2.1 standard deviations in total testosterone was associated with a 25% increase in mortality
  • Erectile dysfunction is an established marker for future cardiovascular risk and the major presenting symptom leading to a diagnosis of low testosterone
  • There is a considerable body of evidence that low testosterone is associated with increased cardiovascular and cancer mortality
  • ...1 more annotation...
  • There is considerable evidence of modest cardiac and metabolic benefits that are shown to reduce cardiovascular risk plus sexual, mood, and quality of life changes associated with restoring testosterone levels
  • Nathan Goodyear on 27 Jan 15
     
    low Testosterone is associated with increased mortality in men and Testosterone therapy in men with low T is associated with a reduction in mortality in men.
Nathan Goodyear

EMAS position statement: Testosterone replacement therapy in the aging male 0f. - PubMe... - 0 views

www.ncbi.nlm.nih.gov/...26614257

low T low Testosterone Testosterone testosterone therapy obesity metabolic syndrome diabetes ED osteoporosis male aging hormones

shared by Nathan Goodyear on 07 Dec 15 - No Cached
  • Nathan Goodyear on 07 Dec 15
     
    we need to get away from expert opinion statements like this. Not that their conclusions are incorrect; but it promotes laziness among physicians.  We physicians need to take control over the data by which we practice medicine and the only way we can do that is to read it.
Nathan Goodyear

Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside - 0 views

www.ncbi.nlm.nih.gov/...PMC5686300

nagalase Gc-MAF cancer

shared by Nathan Goodyear on 29 Jan 18 - No Cached
  • MAF precursor activity has also been lost or reduced after Gc-globulin treatment in some cancer cell lines
  • This appears to result from the deglycosylated ɑ-N-acetylgalactosaminidase (nagalase) secreted from cancerous cells
  • Nagalase has been detected in many cancer patients, but not in healthy individuals
  • ...31 more annotations...
  • Studies have shown that the production of nagalase has a mutual relationship with Gc-MAF level and immunosuppression
  • It has been demonstrated that serum levels of nagalase are good prognosticators of some types of cancer
  • The nagalase level in serum correlates with tumor burden and it has been shown that Gc-MAF therapy progresses, nagalase activity decreases
  • It has been shown that Gc-MAF can inhibit the angiogenesis induced by pro-inflammatory prostaglandin E1
  • The effect of Gc-MAF on chemotaxis or activation of tumoricidal macrophages is likely the main mechanism against angiogenesis.
  • Administration of Gc-MAF stimulates immune-cell progenitors for extensive mitogenesis, activates macrophages and produces antibodies. “This indicates that Gc-MAF is a powerful adjuvant for immunization.”
  • Cancer cell lines do not develop into tumor genes in mouse models after Gc-MAF-primed immunization (29-31) and the effect of Gc-MAF has been approved for macrophage stimulation for angiogenesis, proliferation, migration and metastatic inhibition on tumors induced by MCF-7 human breast cancer cell line
  • The protocol included: "a high dose of second-generation Gc-MAF (0.5 ml) administered twice a week intramuscularly for a total of 21 injections.”
  • Yamamoto et al. showed that the administration of Gc-MAF to 16 patients with prostate cancer led to improvements in all patients without recurrence
  • Inui et al. reported that a 74-year-old man diagnosed with prostate cancer with multiple bone metastases was in complete remission nine months after initiation of GcMAF therapy simultaneously with hyper T/NK cell, high-dose vitamin C and alpha lipoic acid therapy
  • It has also been approved for non-neoplastic diseases such as autism (41), multiple sclerosis (42, 43), chronic fatigue syndrome (CFS) (40), juvenile osteoporosis (44) and systemic lupus erythematous (45).
  • Gc-MAF has been verified for use in colon, thyroid (38), lung (39), liver, thymus (36), pancreatic (40), bladder and ovarian cancer and tongue squamous carcinoma
  • Prostate, breast, colon, liver, stomach, lung (including mesothelioma), kidney, bladder, uterus, ovarian, head/neck and brain cancers, fibrosarcomas and melanomas are the types of cancer tested thus far
  • weekly administration of 100 ng Gc-MAF to cancer at different stages and types showed curative effects at different follow-up times
  • this treatment has been suggested for non-anemic patients
  • Studies have shown that weekly administration of 100 ng Gc-MAF to cancer patients had curative effects on a variety of cancers
  • Because the half-life of the activated macrophages is approximately one week, it must be administered weekly
  • In vivo weekly intramuscular administration of Gc-MAF (100 ng) for 16-22 weeks was used to treat patients with breast cancer
  • individuals harboring different VDR genotypes had different responses to Gc-MAF and that some genotypes were more responsive than others
  • Administration of Gc-MAF for cancer patients exclusively activates macrophages as an important cell in adaptive immunity
  • Gc-MAF supports humoral immunity by producing, developing and releasing large quantities of antibodies against cancer. Clinical evidence from a human model of breast cancer patients supports this hypothesis
  • There is also evidence that confirms the tumoricidal role of Gc-MAF via Fc-receptor mediation
  • It is likely that the best therapeutic responses will be observed when the nutritional and inflammatory aspects are taken together with stimulation of the immune system
  • it should be noted that no harmful side effects of Gc-MAF treatment have been reported, even when it was successfully administered to autistic children
  • The natural activation mechanism of macrophages by Gc-MAF is so natural and it should not have any side effects on humans or animal models even in cell culture
  • Besides the Gc-MAF efficacy on macrophage activity, it can be a potential anti-angiogenic agent (28) and an inhibitor of the migration of cancerous cells in the absence of macrophages (47).
  • Activating or modifying natural killer cells, dendritic cells, DC, CTL, INF and IL-2 have all been recommended for cancer immunotherapy
  • It has been reported that nagalase cannot deglycosylate Gc-MAF as it has specificity for Gc globulin alone
  • inflammation-derived macrophage activation with the participation of B and T lymphocytes is the main mechanism
  • macrophages highly-activated by the addition of Gc-MAF can show tumoricidal activity
  • Previous clinical investigations have confirmed the efficacy of Gc-MAF. In addition to activating existing macrophages, Gc-MAF is a potent mitogenic factor that can stimulate the myeloid progenitor cells to increase systemic macrophage cell counts by 40-fold in four days
  • Nathan Goodyear on 29 Jan 18
     
    great review on Gc-MAF in cancer.  An increase in nagalase blocks Gc-protein to Gc-MAF activity leaving the host immune system compromised.
1 - 7 of 7
Showing 20▼ items per page